Britain Secures 60 Million Doses of Sanofi/GSK COVID-19 Vaccine
LONDON/PARIS (Reuters) - Britain has signed a deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi and GlaxoSmithKline , it said on Wednesday, its fourth such arrangement as the race to tame the pandemic heats up.
FILE PHOTO: The logo of Sanofi is seen during the annual results news conference in Paris, France, February 6, 2020. REUTERS/Benoit Tessier
No vaccine has yet been approved for COVID-19, the respiratory disease caused by the new coronavirus that has killed more than 659,000 people and unleashed economic havoc worldwide.
Financial terms of the agreement were not disclosed. Sanofi and GSK confirmed in a statement that regulatory approval for their vaccine could be achieved by the first half of 2021 if clinical data was positive.
It is Sanofi and GSK's first deal to supply their experimental COVID-19 vaccine to a country, and British ministers have stressed the importance of securing supplies of a range of candidates early.
"The fact remains that there are no guarantees," said business minister Alok Sharma.
"It is important that we secure early access to a diverse range of promising vaccine candidates ... to increase our chances of finding one that works."
FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera
With more than 20 vaccines in human trials, the move will stir concerns that rich countries, including the United States and European Union members, are scooping doses in advance, potentially to the detriment of poorer nations.
Last week, Britain struck deals for 30 million doses of an experimental BioNTech/Pfizer vaccine, and a deal in principle for 60 million doses of Valneva's potential shot.
That followed a previously announced pact with AstraZeneca for 100 million doses of its potential vaccine, being developed in partnership with Oxford university.
The Sanofi/GSK vaccine combines Sanofi's S-protein COVID-19 antigen and GSK's pandemic adjuvant technology, and the first clinical trials are expected in September.
Adjuvants are efficacy boosters that play a vital role in many traditional vaccines. Sanofi and GSK's vaccine uses a different approach than either Oxford/AstraZeneca or Pfizer/Biontech vaccines.
Sanofi and GSK said talks with the European Union, Italy and France to supply their vaccine were ongoing.
The two firms hope to clinch a deal soon to provide 300 million doses to the EU, though two sources told Reuters that negotiations had stalled.
Britain decided against joining the EU's vaccine purchase scheme in order to strike its own deals.